Egilok 100 mg tablets 60 (Metoprolol)

Size chart
Women's clothing size
Euro 32/34 36 38 40
USA 0/2 4 6 8
Bust(in) 31-32 33 34 36
Bust(cm) 80.5-82.5 84.5 87 92
Waist(in) 24-25 26 27 29
Waist(cm) 62.5-64.5 66.5 69 74
Hips(in) 34-35 36 37 39
Hips(cm) 87.5-89.5 91.5 94 99
How To Measure Your Bust

With your arms relaxed at your sides, measure around the fullest part of your chest.

How To Measure Your Waist

Measure around the narrowest part of your natural waist, generally around the belly button. To ensure a comfortable fit, keep one finger between the measuring tape and your body.

Volume discounts

Quantity Unit discount You Save
2 30% $12.96
3 35% $22.68
4 44% $38.02
 Customer ratings and reviews
Nobody has posted a review yet
in this language
Add to compare0
Add to wishlist
Active ingredient
100 mg.
Active substance: metoprolol tartrate 100 mg.
Excipients: microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide colloidal anhydrous, povidone, magnesium stearate.
Pharmacological properties

Cardioselective beta 1 -adrenergic blocker without internal sympathomimetic activity. It has a hypotensive, antianginal and antiarrhythmic effect. Reduces the automatism of the sinus node, reduces heart rate, slows down AV-conduction, reduces contractility and excitability of the myocardium, reduces the minute volume of the heart, reduces the need for myocardium in oxygen. Suppresses the stimulating effect of catecholamines on the heart during physical and psycho-emotional stress.

It causes a hypotensive effect, which stabilizes by the end of the 2nd week of course use. With angina pectoris, metoprolol reduces the frequency and severity of attacks. Normalizes heart rate with supraventricular tachycardia and atrial fibrillation. With myocardial infarction, it helps to limit the zone of ischemia of the heart muscle and reduces the risk of developing fatal arrhythmias, reduces the possibility of relapse of myocardial infarction. When used in medium therapeutic doses, it has a less pronounced effect on the smooth muscles of the bronchi and peripheral arteries than non-selective beta-blockers.

Indications for use
  • arterial hypertension (in monotherapy or in combination with other antihypertensive drugs);
  • functional disorders of cardiac activity, accompanied by tachycardia;
  • IHD (secondary prevention of myocardial infarction, prevention angina attacks);
  • heart rhythm disturbances (supraventricular arrhythmias, ventricular extrasystole);
  • hyperthyroidism (as part of complex therapy);
  • prevention of migraine attacks.
  • cardiogenic shock;
  • AV blockade of II and III degrees;
  • sinoatrial blockade;
  • CCSU;
  • sinus bradycardia (heart rate <50 beats / min);
  • heart failure in the stage of decompensation;
  • severe peripheral circulatory disorders;
  • age up to 18 years (due to the lack of sufficient clinical data);
  • simultaneous intravenous administration of verapamil;
  • severe form of bronchial asthma;
  • pheochromocytoma without the simultaneous use of alpha-blockers;
  • hypersensitivity to metoprolol or any other component of the drug;
  • hypersensitivity to other beta-blockers.

Due to insufficient clinical data, Egiolok ® contraindicated in acute myocardial infarction, accompanied by heart rate <45 beats / min, with an interval of PQ >240 ms, and systolic blood pressure <100 mm Hg.

With caution, the drug should be prescribed for diabetes mellitus; metabolic acidosis; bronchial asthma; COPD; renal / hepatic insufficiency; myasthenia gravis; pheochromocytoma (with simultaneous use with alpha-blockers); thyrotoxicosis; AV-blockade of I degree, depression (including in the anamnesis); psoriasis; obliterating diseases of peripheral vessels (intermittent claudication, Raynaud's syndrome); pregnancy; during lactation; elderly patients; patients with a burdened allergic history (possibly reduced response when used adrenaline).

Use in pregnancy and lactation

The use of the drug is not recommended during pregnancy. The use of the drug is possible only when the intended benefit to the mother exceeds the potential risk to the fetus. If it is necessary to prescribe the drug during pregnancy, careful monitoring of the condition of the fetus and newborn for 48-72 hours after childbirth is necessary, since the development of bradycardia, arterial hypotension, hypoglycemia and respiratory depression is possible.

Despite the fact that when using the drug in therapeutic doses, only a small amount of metoprolol is excreted in breast milk, the condition of the newborn should be monitored (bradycardia is possible). The use of the drug during lactation is not recommended. If necessary, the drug Egilok ® breastfeeding should be discontinued during lactation.

Use in case of violations Liver

In cirrhosis of the liver, a dose change is usually not required due to the low binding of metoprolol to blood plasma proteins. With severe liver failure (for example, after portocaval bypass surgery), it may be necessary to reduce the dose of the drug Egilok ® .

With caution, the drug should be prescribed for liver failure.

Use in renal dysfunction

In patients with impaired renal function, no change in the dosing regimen is required.

With caution, the drug should be prescribed for renal failure.

Use in children
Due to the lack of sufficient clinical data, the drug is not recommended for use in children and adolescents under the age of 18 years.
Use in elderly patients
With caution, the drug should be prescribed to elderly patients Age.
Special instructions

When prescribing the drug Egilok ® heart rate and blood pressure should be monitored regularly. It is necessary to teach the patient the method of calculating heart rate and instruct about the need for medical advice at heart rate <50 beats / min.

In patients with diabetes mellitus, blood glucose levels should be regularly monitored and, if necessary, the dose of insulin or oral hypoglycemic drugs should be adjusted.

When using the drug in a dose exceeding 200 mg / day, cardioselectivity decreases.

The appointment of Egilok to patients with chronic heart failure is possible only after reaching the stage of compensation.

In patients taking Egilok ® , it is possible to increase the severity of hypersensitivity reactions (against the background of a burdened allergic history) and the lack of effect from the introduction of conventional doses of epinephrine (adrenaline).

Anaphylactic shock may be more severe in patients taking Egilok ® .

Against the background of the use of Egilok, it is possible to aggravate the symptoms of peripheral circulatory disorders.

Egilok ® should be canceled gradually, consistently reducing its dose for 14 days. With a sharp cessation of treatment, it is possible to increase attacks of angina pectoris and the risk of developing coronary disorders. During the period of withdrawal of the drug, patients with coronary artery disease should be under close medical supervision.

With angina pectoris of tension, the selected dose of the drug Egilok ® must provide a resting heart rate of 55-60 beats / min, at load - no more than 110 beats / min.

Patients using contact lenses should take into account that against the background of treatment with beta-blockers, it is possible to reduce the production of tear fluid.

Egilok ® can mask some clinical manifestations of hyperthyroidism (for example, tachycardia). Abrupt withdrawal of the drug in patients with thyrotoxicosis is contraindicated, since it can increase the symptoms.

In diabetes mellitus, taking Egilok can mask tachycardia caused by hypoglycemia. Unlike non-selective beta-blockers, it practically does not increase insulin-induced hypoglycemia and does not delay the restoration of blood glucose concentration to a normal level.

When prescribing metoprolol to patients with bronchial asthma, simultaneous use of beta is necessary 2 - Adrenomimetics.

In patients with pheochromocytoma Egilok ® should be used in combination with alpha-blockers.

Before any surgical intervention, it is necessary to inform the surgeon / anesthesiologist about the therapy with Egilok (choice a drug for general anesthesia with minimal negative inotropic effect); cancellation of the drug is not required.

Drugs that reduce the supply of catecholamines (for example, reserpine) can enhance the effect of beta-blockers, so patients taking such combinations of drugs should be under constant medical supervision for excessive reduction in blood pressure or bradycardia.

When prescribing the drug to elderly patients, liver function should be regularly monitored. Correction of the dosing regimen is required only in case of increasing bradycardia in elderly patients (<50 beats / min), a pronounced decrease in blood pressure (systolic blood pressure <100 mm Hg), AV blockade, bronchospasm, ventricular arrhythmias, severe violations of liver function. Sometimes it is necessary to stop treatment.

Patients with severe renal insufficiency are advised to monitor kidney function.

Should conduct special monitoring of the condition of patients with depressive disorders. In the case of the development of depression caused by the use of beta-blockers, therapy should be discontinued.

If progressive bradycardia occurs, the dose should be reduced or the drug should be discontinued.

Use in pediatrics

Due to the lack of sufficient clinical data, the drug is not recommended for use in children and adolescents under the age of 18 years.

Influence on the ability to drive vehicles and control mechanisms

Caution must be exercised when driving vehicles and when engaging in potentially hazardous activities that require increased concentration of attention (risk of dizziness and fatigue).

Dosage and Administration
Egilok is prescribed for arterial hypertension in a daily dose of 50-100 mg / day in 1 or 2 doses. At insufficient therapeutic effect is possible a gradual increase in the daily dose to 100-200 mg.
With angina pectoris, supraventricular arrhythmias, for the prevention of migraine attacks, it is prescribed at a dose of 100-200 mg / day in 2 doses (morning and evening).
For the secondary prevention of myocardial infarction, it is prescribed in an average daily dose of 200 mg in 2 doses (morning and evening).
With functional disorders of cardiac activity, accompanied by tachycardia, it is prescribed in a daily dose of 100 mg in 2 doses (morning and evening).
Tablets should be taken orally during or immediately after a meal. Tablets can be divided in half, but not chewed.

Symptoms: severe sinus bradycardia, dizziness, nausea, vomiting, cyanosis, arterial hypotension, arrhythmia, ventricular extrasystole, bronchospasm, fainting; with acute overdose - cardiogenic shock, loss of consciousness, coma, AV-blockade up to the development of complete transverse blockade and cardiac arrest, cardialgia.
The first signs of an overdose appear 20 minutes-2 hours after administration.
Treatment: gastric lavage, the appointment of adsorbents, symptomatic therapy: with a pronounced decrease in blood pressure - Trendelenburg position, in case of acute arterial hypotension, bradycardia and threatening heart failure - intravenous (with an interval of 2-5 minutes), the introduction of beta-adrenergic stimulants or intravenous administration of 0.5-2 mg of atropine sulfate, in the absence of a positive effect - dopamine, dobutamine or norepinephrine. As follow-up measures, it is possible to prescribe 1-10 mg of glucagon, the formulation of a transvenous intracardial pacemaker. With bronchospasm - intravenous administration of beta2-adrenergic stimulants, with convulsions - slow intravenous administration of diazepam. Metoprolol is poorly excreted by hemodialysis.

Side effects
From the side of the central nervous system and peripheral nervous system: increased fatigue, weakness, headache pain, slowing down the speed of mental and motor reactions; rarely - paresthesia in the limbs, depression, anxiety, decreased ability to concentrate, drowsiness, insomnia, nightmares, confusion or short-term memory impairment, asthenic syndrome, muscle weakness.
From the senses: rarely - decreased vision, decreased secretion of tear fluid, xerophthalmos, conjunctivitis, tinnitus.
From the cardiovascular system: sinus bradycardia, palpitations, decreased blood pressure, orthostatic hypotension; rarely - a decrease in myocardial contractility, a temporary aggravation of the symptoms of chronic heart failure, arrhythmia, increased peripheral circulatory disorders (cooling of the lower extremities, Raynaud's syndrome), myocardial conduction disorders; in isolated cases - AV-blockade, cardialgia.
From the digestive system: nausea, vomiting, abdominal pain, diarrhea, constipation, dry mouth, change in taste; increased activity of hepatic transaminases; rarely - hyperbilirubinemia.
Dermatological reactions: urticaria, skin itching, rash, exacerbation of psoriasis, psoriasis-like skin changes, skin flushing, exanthema, photodermatosis, increased sweating, reversible alopecia.
From the respiratory system: nasal congestion, difficulty exhaling (bronchospasm when prescribed in high doses or in predisposed patients), shortness of breath.
From the endocrine system: hypoglycemia (in patients receiving insulin); rarely - hyperglycemia.
From the hematopoietic system: thrombocytopenia, agranulocytosis, leukopenia.
Other: back or joint pain, slight increase in body weight, decreased libido and / or potency.
Storage conditions
The drug should be stored out of the reach of children at a temperature of 15 ° to 25 ° C.
Shelf life - 5 years.
Read more
Product Details

Data sheet

EGIS Pharmaceuticals
Dosage form
100 mg
Number of tablets
INN Russian
Russian title
No comments

Be the first to write your review !



Create a free account to save loved items.

Sign in

Create a free account to use wishlists.

Sign in